PharmAthene to present its biological/ chemical weapons countermeasure program data at the HHS PHEMCE workshop

PharmAthene, Inc.Dec 2 2009

PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the Company will participate in and present data at the HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) workshop and BARDA Industry Day taking place in Washington, DC Dec. 2-4, 2009.

"As a company focused on the biosecurity of the country, we are honored to be presenting at this vital conference," said PharmAthene President and Chief Executive Officer, David P. Wright. "The PHEMCE conference comes at a critical time in our Nation's history as we collectively wrestle with the many challenges of providing adequate stockpiles of modern vaccines ready for a host of potential emergencies."

The HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Stakeholders Workshop 2009 and BARDA Industry Day will bring together public and private sector stakeholders for a dynamic dialogue on the current state of medical countermeasure preparedness, PHEMCE initiatives in the past year, and plans for moving forward to enhance national capabilities to respond to a public health emergency.

"This HHS sponsored workshop is shedding much needed light on a dangerously neglected area," commented former Secretary of Health and Human Services, Tommy Thompson. "As we have learned with the H1N1 virus, it's imperative to have adequate stockpiles of proven vaccine ready for an emergency. The HHS PHEMCE workshop is very timely given the WMD Commission's conclusion that terrorists are much more likely to attack America with a biological weapon than a nuclear weapon. Now that our national experts have made this warning clear, we need to take the immediate steps necessary to protect against potential biological attacks against the U.S. homeland. In particular, we need to move forward efforts to build and stockpile appropriate biological countermeasures, such as next-generation anthrax vaccines, recombinant influenza vaccines, and novel antivirals."